BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24200760)

  • 21. Extended-release ranolazine: critical evaluation of its use in stable angina.
    Truffa AA; Newby LK; Melloni C
    Vasc Health Risk Manag; 2011; 7():535-9. PubMed ID: 21915171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ranolazine for chronic stable angina.
    Nash DT; Nash SD
    Lancet; 2008 Oct; 372(9646):1335-41. PubMed ID: 18929905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ranolazine: a new option in the management of chronic stable angina.
    Dobesh PP; Trujillo TC
    Pharmacotherapy; 2007 Dec; 27(12):1659-76. PubMed ID: 18041887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
    Thadani U
    Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ranolazine--an additional anti-anginal drug].
    Michels G; Kochanek M; Hoppe UC
    Dtsch Med Wochenschr; 2010 Oct; 135(41):2037-40. PubMed ID: 20925013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. At the dawn of a new era in treating angina pectoris, or just another antianginal drug? Some considerations about ranolazine.
    Bălan H
    Rom J Intern Med; 2010; 48(4):361-9. PubMed ID: 21528766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranolazine: a review of its use in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Drugs; 2006; 66(5):693-710. PubMed ID: 16620147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
    JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ranolazine: an antianginal drug with antiarrhythmic properties.
    Tamargo J; Caballero R; Delpón E
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
    Maier LS
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-anginal and anti-ischemic effects of late sodium current inhibition.
    Wimmer NJ; Stone PH
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):69-77. PubMed ID: 23247666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ranolazine on cardiovascular system.
    Bonadei I; Vizzardi E; Quinzani F; Piovanelli B; Rovetta R; D'Aloia A; Cas LD
    Recent Pat Cardiovasc Drug Discov; 2011 Sep; 6(3):215-21. PubMed ID: 21867482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
    Kohn CG; Parker MW; Limone BL; Coleman CI
    Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
    Scirica BM; Morrow DA; Hod H; Murphy SA; Belardinelli L; Hedgepeth CM; Molhoek P; Verheugt FW; Gersh BJ; McCabe CH; Braunwald E
    Circulation; 2007 Oct; 116(15):1647-52. PubMed ID: 17804441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Ranolazine in the treatment of chronic stable angina].
    Gustapane M; Cardillo MT; Biasillo G; Della Bona R
    Clin Ter; 2012; 163(3):231-4. PubMed ID: 22964698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ranolazine: a review of its use in chronic stable angina pectoris.
    Keating GM
    Drugs; 2008; 68(17):2483-503. PubMed ID: 19016575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranolazine in patients with angina and coronary artery disease.
    Scirica BM; Morrow DA
    Curr Cardiol Rep; 2007 Jul; 9(4):272-8. PubMed ID: 17601393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetes and coronary disease: a need for new therapies for an expanding disease burden.
    Lew WY; DeMaria AN
    J Am Coll Cardiol; 2013 May; 61(20):2046-7. PubMed ID: 23500323
    [No Abstract]   [Full Text] [Related]  

  • 40. Trials and tribulations associated with angina and traditional therapeutic approaches.
    Deedwania PC; Carbajal EV; Bobba VR
    Clin Cardiol; 2007 Feb; 30(2 Suppl 1):I16-24. PubMed ID: 18373326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.